Clinical trials: Migraine in Adults
Migraine Disorders
An Observational Study of BOTOX® as Headache Prophylaxis for Chronic Migraine
This is an observational study to describe the long term use of Onabotulinumtoxin A (BOTOX®) as prescribed by the physician for headache prophylaxis in adults with chronic migraine. All treatment decisions lie with the physician.
- Trial name
- NCT01686581
- Testing
- botulinum toxin Type A
- Where
- 77 sites in Germany, Italy and 5 more
- Volunteers
- 641 people
- Sponsor
- Allergan
Migraine, Episodic Migraine
Study of Two Digital Therapeutics for the Prevention of Episodic Migraine
Randomized study of two digital therapeutics for the prevention of episodic migraine
- Conditions
- Migraine, Episodic Migraine, Headache, Headache, Migraine
- Trial name
- ReMMi-D (NCT05853900)
- Testing
- ReMMi-D Digital Therapeutic
- Where
- United States
- Volunteers
- 568 people
- Sponsor
- Click Therapeutics, Inc.
Migraines
Pain Processing in Adults With Migraines
Primary Objective of this study: To assess experimental heat pain responses (pain intensity, pain unpleasantness, pain catastrophizing, emotional reactivity) in migraineurs vs. healthy controls.
- Trial name
- NCT02748577
- Testing
- Questionnaires, Quantitative Sensory Testing (QST) Pain Measurements
- Where
- United States
- Volunteers
- 121 people, healthy volunteers welcome
- Sponsor
- Wake Forest University Health Sciences
Migraine Headache
A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack
Intraject is a needle-free, single use, disposable, subcutaneous delivery system pre-filled with 6mg Sumatriptan to be used by patients to treat acute migraine treatment.
- Trial name
- NCT00530517
- Testing
- Intraject Sumatriptan
- Where
- 4 sites in United States
- Volunteers
- 54 people
- Sponsor
- Zogenix, Inc.
Chronic Migraine
A Two-Arm Study Evaluation H.P. Acthar Injection Gel in Treatment of Chronic Migraines
This small study is to investigate the efficacy of Acthar in the treatment of chronic migraine in patients who have failed multiple treatments, including Botox (which is defined as having <30% reduction from baseline in the…
- Trial name
- NCT01813591
- Testing
- H.P. Acthar Gel
- Where
- 4 sites in United States
- Volunteers
- 20 people
- Sponsor
- Dent Neuroscience Research Center
Migraine
Randomized Trial in Adult Participants With Acute Migraines
The purpose of this study is to test the safety and efficacy of BHV-3500 (zavegepant) versus placebo in the acute treatment of moderate or severe migraine.
- Trial name
- NCT04571060
- Testing
- Zavegepant
- Where
- 94 sites in United States
- Volunteers
- 1,978 people
- Sponsor
- Pfizer
Migraine
A Study to Investigate the Safety and Efficacy of MEDI0618 Compared to Placebo in Adult Participants With Episodic Migraine
The purpose of this Phase 2 study is to evaluate the safety and efficacy of SC MEDI0618 compared to placebo in participants with episodic migraine.
- Trial name
- AURORA (NCT06602479)
- Testing
- MEDI0618
- Where
- 71 sites in United States, Czechia and 6 more
- Volunteers
- 309 people
- Sponsor
- AbbVie
Migraine With Aura, Migraine Without Aura
A Phase I Study to Study the PK and Safety of Single Doses of STS101, DHE Injection and Nasal Spray in Healthy Subjects
Single-center, single-dose, open-label, 2-part, 3-period crossover (in each part), pharmacokinetic and safety study.
- Conditions
- Migraine With Aura, Migraine Without Aura, Migraine
- Trial name
- NCT03874832
- Testing
- Dihydroergotamine
- Where
- United States
- Volunteers
- 46 people, healthy volunteers welcome
- Sponsor
- Satsuma Pharmaceuticals, Inc.
Migraine
Efficacy and Safety Study of Rimegepant in Episodic Migraine Prevention With Multiple Dosing Regimens
The purpose of this study is to compare the efficacy and safety of daily and every other day dosing of rimegepant to placebo as a preventive treatment for episodic migraine.
- Trial name
- NCT05217927
- Testing
- Rimegepant 75mg daily dosing, Rimegepant 75mg every other day dosing
- Where
- 107 sites in United States, Austria and 8 more
- Volunteers
- 1,415 people
- Sponsor
- Pfizer
Migraine
Study to Assess Function and Satisfaction of Oral Ubrogepant in Adult Participants After Multiple Migraine Attacks In Canada
Migraine is a neurological disease characterized by moderate or severe headache, associated with nausea, vomiting, and/or sensitivity to light and sound.
- Trial name
- NCT06692881
- Where
- 13 sites in Canada
- Volunteers
- 178 people
- Sponsor
- AbbVie
Migraine
Study Evaluating the Efficacy, Safety, and Tolerability of ASY202 (Dihydroergotamine Mesylate [DHE] Inhalation Powder Delivered Via a Multidose Dry Powder Inhaler) for the Acute Treatment of Migraine in Adult Patients
This study is testing an investigational inhaled migraine medication to see how well it works, how safe it is, and how well people tolerate it.
- Trial name
- NCT07646613
- Testing
- ASY202
- Where
- 20 sites in United States
- Volunteers
- 108 people
- Sponsor
- Aspeya, Inc.
Migraine Disorders, Brain, Healthy Adult Participants
Effect of Atogepant on the Vestibulo-Ocular Reflex in Healthy Adults and Adults With Migraine
Researchers want to find out how a substance in the body called CGRP affects balance. CGRP (calcitonin gene-related peptide) is a small protein involved in migraine. Several approved migraine medicines work by blocking it.
- Conditions
- Migraine Disorders, Brain, Healthy Adult Participants, Vestibulo-Ocular Reflex
- Trial name
- VOR-GRIP (NCT07826910)
- Testing
- Atogepant 60 mg
- Where
- Switzerland
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Konrad Peter Weber
Migraine
Study of Oral Atogepant Tablets to Assess Safety and Efficacy in Adult Participants With Migraine
A migraine attack is a moderate or severe headache that usually occurs on one side of the head and is often accompanied by throbbing, sensitivity to light, sensitivity to sound, nausea, or other symptoms.
- Trial name
- ATO ACUTE (NCT06241313)
- Testing
- Atogepant
- Where
- 149 sites in Belgium, China and 13 more
- Volunteers
- 2,158 people
- Sponsor
- AbbVie
Chronic Migraine
A Study Investigating Peripheral Cryoneurolysis in Adults With Chronic Migraine
The trial is a research study that tests a freezing technique called cryoneurolysis to see if it helps relieve pain in adults with chronic migraine. Chronic migraine is a condition that causes moderate to severe headache.
- Trial name
- NCT06554886
- Testing
- Cryoneurolysis
- Where
- Norway
- Volunteers
- 12 people
- Sponsor
- St. Olavs Hospital
Migraine
Initiating Early Control of Migraine Pain and Associated Symptoms
AXS-07 is an oral, investigational medicine consisting of MoSEIC meloxicam and rizatriptan, which is being developed for the acute treatment of migraine with or without aura in adults.
- Trial name
- INTERCEPT (NCT04163185)
- Testing
- AXS-07 (MoSEIC meloxicam and rizatriptan)
- Where
- 41 sites in United States
- Volunteers
- 302 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine
Open-Label Study of AXS-07 for the Acute Treatment of Migraine in Adults With a Prior Inadequate Response to an Oral CGRP Inhibitor (EMERGE)
This is a multicenter, open-label trial to evaluate the efficacy and safety of AXS-07 in subjects with migraine attacks and prior inadequate response to oral CGRP inhibitors.
- Trial name
- NCT05550207
- Testing
- AXS-07 (meloxicam-rizatriptan)
- Where
- 31 sites in United States
- Volunteers
- 100 people
- Sponsor
- Axsome Therapeutics, Inc.
Migraine Disorders
A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses.
This is a pharmacokinetic (PK) study designed to investigate a combination product containing sumatriptan succinate and naproxen sodium administered at 3 single doses (10mg sumatriptan/60mg naproxen sodium, 30mg sumatriptan/180mg…
- Trial name
- NCT00989625
- Testing
- This is a pharmacokinetic study (Treximet)
- Where
- 3 sites in United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Episodic Migraine
Study of Sustained Benefit of AMG334 in Adult Episodic Migraine Patients
The purpose of this study is to compare the sustained long-term benefit between two treatment paradigms of migraine prophylactic agents (erenumab versus a control arm of oral prophylactics) in episodic migraine patients who have…
- Trial name
- NCT03927144
- Testing
- AMG334, Oral Prophylactic
- Where
- 112 sites in United States, Argentina and 16 more
- Volunteers
- 621 people
- Sponsor
- Amgen
Migraine
Single Ascending Dose Study to Investigate the Safety and Pharmacokinetics of XC101-D13H in Healthy Adult Subjects
This is a randomized, double-blind, placebo-controlled, parallel-group single ascending dose (SAD) study. There are 4 cohorts of 8 subjects (8 active and 2 placebo) planned for evaluation under fasting conditions.
- Trial name
- NCT04104399
- Testing
- XC101-D13H
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Xoc Pharmaceuticals
Migraine, Without Aura
TREXIMET (Formerly Known as TREXIMA) for the Acute Treatment of Probable Migraine (ICHD-II 1.6.1)
This study was designed to determine the efficacy and tolerability of TREXIMET (formerly known as TREXIMA) compared to placebo for the acute treatment of probable migraine, a sub-type of migraine.
- Trial name
- NCT00387881
- Testing
- sumatriptan succinate / naproxen sodium
- Where
- 70 sites in United States
- Volunteers
- 679 people
- Sponsor
- GlaxoSmithKline